drugset / Trial / NCT02577458

Study of the Combination of CM082 With Everolimus in Patients With mRCC

NCT02577458

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Advanced Renal Cell Carcinoma.

Timeline

Start
2015-09
Primary completion
2018-03
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CM082 Unknown Oral
Background Everolimus Small molecule Oral

Indications